Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Breast Neoplasms
  • Doxorubicin

abstract

  • Single-agent TLC D-99 produces less cardiotoxicity than doxorubicin, while providing comparable antitumor activity.

authors

publication date

  • January 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.10201

PubMed ID

  • 11815957

Additional Document Info

start page

  • 25

end page

  • 36

volume

  • 94

number

  • 1